PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2012 | 2 | 4 | 255-261
Article title

Chemioterapia w guzach neuroendokrynnych układu pokarmowego (GEP-NEN)

Content
Title variants
EN
Chemotherapy in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN)
Languages of publication
PL
Abstracts
EN
Approximately two-thirds of malignant GEP-NENs are metastatic at discovery. Chemotherapy with platinum and etoposide is a standard therapy for poorly differentiated GEP-NEC. For well-differentiated pancreatic GEP-NEN association of streptozotocin/doxorubicin and/or 5-Fu is a standard. However, it requires comparison with other established therapies. International recommendations have suggested abandoning the use of classical cytotoxics in the treatment of metastatic midgut tumours in favour of more suitable options when applicable.
PL
Nowotwory neuroendokrynne układu pokarmowego w chwili rozpoznania choroby są w stadium rozsianym u ok. 2/3 chorych. Chemioterapia z użyciem schematu cisplatyna + etopozyd pozostaje standardem w przypadku zaawansowanych postaci niskozróżnicowanych raków neuroendokrynnych (NEC G3 wg klasyfikacji WHO z 2010 r.). W przypadku dobrze zróżnicowanych nowotworów neuroendokrynnych trzustki streptozotocyna, doksorubicyna i/lub 5-Fu są uważane za chemioterapię standardową, mimo że nie ma randomizowanych badań porównujących ją z innymi terapiami. Międzynarodowe wytyczne nie rekomendują stosowania chemioterapii w rozsianych nowotworach neuroendokrynnych pochodzących ze środkowego odcinka prajelita (midgut). Chorzy ci powinni być kwalifikowani do innego typu leczenia.
Discipline
Publisher

Journal
Year
Volume
2
Issue
4
Pages
255-261
Physical description
Contributors
  • Oddział Chemioterapii, Klinika Onkologii Centrum Onkologii􀂉 Instytut im. Marii Skłodowskiej-Curie w Warszawie, akolasinska@coi.pl
References
  • Rindi B., Bordi C.: Etiology, molecular pathogenesis and genetics. Best Pract. Res. Clin. Gastroenterology 2005; 19: 519-534.
  • Gaur P., Sceusi E.L., Samuel S. et al.: Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011; 141: 1728-1737.
  • Modlin I.M., Oberg K., Chung D.C. et al.: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9: 61-72.
  • Kos-Kudła B.: Polskie zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (GEP NET). Nowotwory J. of Oncology 2006; 56: 584-589.
  • Oberg K.: Pancreatic endocrine tumors. Semin. Oncol. 2010; 37: 594-618.
  • Kulke M.H., Siu L.L., Tepper J.E. et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 2011; 29: 934-943.
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Version 1.2011 [online: http://www.nccn.org].
  • Bosman F., Carneiro F., Hruban R. et al.: WHO classification of tumors of digestive system. Lyon, IARC Press 2010.
  • Kennedy A.S., Dezarin W.A., McNeillie P. et al.: Radioembolization for unresectable Neuroendocrine Hepatic Metastatic Using Resin 90Y Microspheres: Early Results in 148 Patients. Am. J. Clin. Oncol. 2008 Jun; 31(3): 271-9.
  • Moertel C.G., Kvols L.K., O’Connell M.U. et al.: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasm. Cancer 1991; 68: 227-232.
  • Mitry E., Baudin E., Ducreux M. et al.: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer 1999; 81: 1351-1355.
  • Hainsworth J.D., Spigel D.R., Litchy S. et al.: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma a Minnie Pearl Cancer Research Network Study. J. Clin. Oncol. 2006; 24: 3548-3554.
  • Bajetta E., Catena L., Procopio G. et al.: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 2007; 59: 632-642.
  • Turner N.C., Strauss S.J., Sarker D. et al.: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 2010; 102: 1106-12.
  • Okita N.T., Kato K., Takahari D. et al.: Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011; 14: 161-5.
  • DiMeglio G., Massacesi C., Radice D. et al.: Carboplatin with etoposide in patients with extrapulmonary aggressive neuroendocrine carcinoma. J. Clin. Oncology 2010; 28: abstract e13072.
  • Broder L.E., Carter S.K.: Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann. Intern. Med. 1973; 79: 101-107.
  • Moertel C.G., Hanley J.A., Johnson L.A.: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 1980; 303: 1189-94.
  • Moertel C.G., Lefkopoulo M., Lipsitz S. et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med 1992; 326: 519-23.
  • Öberg K.: Management of neuroendocrine tumours. Ann. Oncol. 2004; suppl. 4: 293-8.
  • O’Toole D., Hentic O., Corcos O., Ruszniewski P.: Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80 (suppl. 1): 79-84.
  • Cheng P.N., Saltz L.B.: Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86: 944-8.
  • McCollum A.D., Kulke M.H., Ryan D.P. et al.: Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic neuroendocrine tumors. Am. J. Clin. Oncol. 2004; 27: 485-488.
  • Delaunoit T., Ducreux M., Boige V. et al.: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur. J. Cancer 2004; 40: 515-20.
  • Kouvaraki M.A., Ajani J.A., Hoff P. et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 2004; 22: 4762-71.
  • Fjallskog M.L., Janson E.T., Falkmer U.G. et al.: Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 55-58.
  • Corrie P., Caplin M., Reed N.: Treatment of advanced neuroendocrine tumors. Results of the UKINETS and NCRI randomized phase II NET01 trial. J. Clin. Oncol. 2012; 30 (suppl.): abstr. 4121.
  • Ramanathan R.K., Cnaan A., Hahn R.G. et al.: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: Study of the Eastern Cooperative Oncology Group E-6282. Ann. Oncol. 2001; 12: 1139-1143.
  • Kulke M., Stuart K., Enzinger P.C. et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006; 24: 401-406.
  • Kulke M.H., Stuart K., Earle C.C. et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2006; 24(18S): 4044.
  • Strosberg J.R., Fine R.L., Choi J. et al.: First Line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
  • Ekeblad S., Sundin A., Janson E.T. et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007; 13: 2986-2991.
  • Kulke M.H., Hornick J.L., Frauenhoffer C. et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009; 15: 388-345.
  • Cassier P.A., Walter T., Eymard B. et al.: Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-differentiated Neuroendocrine Carcinomas. Cancer 2009; 115: 3392-9
  • Engstrom P.F., Lavin P.T., Moertel C.G. et al.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 1984; 2: 1255-1259.
  • Moertel C.G., Hanley J.A.: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials 1979; 2: 327-34.
  • Frame J., Kelsen D., Kemeny N. et al.: A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am. J. Clin. Oncol. 1988; 11: 490-5.
  • Sun W., Lipsitz S., Catalano P. et al.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. 2005; 23: 4897-4904.
  • Bukowski R.M., Tangen C.M., Peterson R.F. et al.: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994; 73: 1505-1508
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-94d1899d-dcd4-474b-9c25-66a6908b0c10
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.